{
  "nodes": [
    {
      "group": "Drugs",
      "ecosystem": "BioVentureHub",
      "company_name": "BioVentureHub",
      "id": "BioVentureHub",
      "turnover_sek": 1730000,
      "amount_of_employees": 300,
      "keywords": "",
      "type_of_company": "",
      "operational_focus": "",
      "value_chain": "",
      "therapy_areas": "",
      "area": "",
      "financing": "",
      "ceo": "",
      "company_website": "",
      "company_linkedIn": "",
      "size_in_visualization": "BVH",
      "image_path": "images/bioventurehub.png"
    },
    {
      "group": "Drugs",
      "ecosystem": "BioVentureHub",
      "company_name": "BVH Companies",
      "id": "BVH_Companies",
      "turnover_sek": 1730000,
      "amount_of_employees": 300,
      "keywords": "",
      "type_of_company": "",
      "operational_focus": "",
      "value_chain": "",
      "therapy_areas": "",
      "area": "",
      "financing": "",
      "ceo": "",
      "company_website": "",
      "company_linkedIn": "",
      "size_in_visualization": "BVH",
      "image_path": "images/bvh_companies.png"
    },
    {
      "group": "Drugs",
      "ecosystem": "GoCo",
      "company_name": "GoCo",
      "id": "GoCo",
      "turnover_sek": 1730000,
      "amount_of_employees": 300,
      "keywords": "",
      "type_of_company": "",
      "operational_focus": "",
      "value_chain": "",
      "therapy_areas": "",
      "area": "",
      "financing": "",
      "ceo": "",
      "company_website": "",
      "company_linkedIn": "",
      "size_in_visualization": "big",
      "image_path": "images/goco.png"
    },
    {
      "group": "Drugs",
      "ecosystem": "Astra",
      "company_name": "AstraZeneca",
      "id": "Astra",
      "turnover_sek": 1730000,
      "amount_of_employees": 300,
      "keywords": "",
      "type_of_company": "",
      "operational_focus": "",
      "value_chain": "",
      "therapy_areas": "",
      "area": "",
      "financing": "",
      "ceo": "",
      "company_website": "",
      "company_linkedIn": "",
      "size_in_visualization": "big",
      "image_path": "images/astrazeneca.png"
    },
    {
      "group": "Drugs",
      "ecosystem": "Astra",
      "company_name": "Alumni",
      "id": "BVH_Alumni",
      "turnover_sek": 1730000,
      "amount_of_employees": 300,
      "keywords": "",
      "type_of_company": "",
      "operational_focus": "",
      "value_chain": "",
      "therapy_areas": "",
      "area": "",
      "financing": "",
      "ceo": "",
      "company_website": "",
      "company_linkedIn": "",
      "size_in_visualization": "BVH",
      "image_path": "images/bvh_alumni.png"
    },
    {
      "group": "Drugs",
      "ecosystem": "Astra",
      "company_name": "USP",
      "id": "BVH_USP",
      "turnover_sek": 1730000,
      "amount_of_employees": 300,
      "keywords": "",
      "type_of_company": "",
      "operational_focus": "",
      "value_chain": "",
      "therapy_areas": "",
      "area": "",
      "financing": "",
      "ceo": "",
      "company_website": "",
      "company_linkedIn": "",
      "size_in_visualization": "BVH",
      "image_path": "images/bvh_usp.png"
    },
    {
      "group": "Drugs",
      "ecosystem": "BioVentureHub",
      "company_name": "Alzinova",
      "id": "Alzinova",
      "turnover_sek": 1730000,
      "amount_of_employees": 3,
      "keywords": "Alzheimer disease, AβCC peptide™ technology",
      "type_of_company": "Drugs",
      "operational_focus": "R&D",
      "value_chain": "Discovery",
      "therapy_areas": "Neurology",
      "area": "Alzheimers",
      "financing": "Listed",
      "ceo": "Torfgård, Kristina",
      "company_logo": "https://www.azbioventurehub.com/content/dam/bioventurehub/images/logo/Alzinova%20logo900x400.png/jcr:content/renditions/cq5dam.web.320.Alzinova%20logo900x400.png",
      "company_website": "https://www.alzinova.com/",
      "company_linkedIn": "https://www.linkedin.com/company/alzinova-ab/",
      "size_in_visualization": "medium",
      "image_path": "images_cropped/alzinova_cropped.png",
      "mission_statement": "Alzinova is specializing in the treatment of Alzheimer’s Disease by targeting Alzinova AB is a Swedish clinical-stage biopharma company specialising in the treatment of Alzheimer’s disease targeting neurotoxic amyloid beta oligomers. The lead candidate, ALZ-101, is being developed as a therapeutic vaccine for the treatment of Alzheimer's. Alzinova’s proprietary AβCC peptide™ technology enables the development of disease-modifying therapies that target the toxic amyloid beta oligomers involved in the onset and progression of the disease with high precision. Alzheimer’s is one of the most common and devastating neurological diseases globally, with of the order of 40 million people afflicted today. In addition, the antibody ALZ-201 is in preclinical development, and the ambition is to expand the pipeline further.the toxic amyloid-β oligomers. Alzinova’s proprietary AβCC peptide™ technology enables the development of disease-modifying therapies that with high precision could target the toxic amyloid-β oligomers involved in the onset and progression of the disease. The lead candidate, ALZ-101, is in late preclinical development as a therapeutic vaccine and is currently being prepared for the first clinical trial in patients with Alzheimer’s disease, in Q2 2021"
    },
    {
      "group": "Diagnostics",
      "ecosystem": "BioVentureHub",
      "company_name": "Antaros Medical",
      "id": "Antaros_Medical",
      "turnover_sek": 116000000,
      "amount_of_employees": 75,
      "keywords": "imaging solutions, human clinical studies, CVRM, ONC, repiratory and neuroscience",
      "type_of_company": "Expert Providers, Diagnostics",
      "operationa_focus": "R&D",
      "value_chain": "Discovery",
      "therapy_areas": "CVRM, Oncology, R&I, Neuro",
      "area": "Imaging",
      "financing": "Private",
      "ceo": "Hulthe, Johannes",
      "company_logo": "https://www.azbioventurehub.com/content/dam/bioventurehub/images/logo/Antaros-Medical.jpg/jcr:content/renditions/cq5dam.web.320.Antaros-Medical.jpg",
      "image_path": "images_cropped/antarosmedical_cropped.png",
      "company_website": "https://antarosmedical.com/",
      "company_linkedin": "https://www.linkedin.com/company/antaros-medical/",
      "size_in_visualization": "medium",
      "mission_statement": "We enable decision-makers in clinical drug development to optimize outcomes and minimize risk in Phase 1b and Phase 2 trials by the use of advanced imaging techniques. We also provide expert support for product differentiation in life cycle management. We specialize in cardio-metabolic conditions and oncology/immuno-oncology."
    },
    {
      "group": "Drugs",
      "ecosystem": "BioVentureHub",
      "company_name": "Cereno Scientific",
      "id": "Cereno_Scientific",
      "turnover_sek": 44800000,
      "amount_of_employees": 1,
      "type_of_company": "Drugs",
      "operationa_focus": "R&D",
      "value_chain": "Research",
      "therapy_areas": "Cardiovascular disease",
      "area": "Cardiovascular",
      "financing": "Listed",
      "ceo": "Sörensen, Sten",
      "company_logo": "https://www.azbioventurehub.com/content/dam/bioventurehub/images/logo/Cereno-logo.png/jcr:content/renditions/cq5dam.web.320.Cereno-logo.png",
      "company_website": "https://cerenoscientific.com/",
      "company_linkedin": "https://www.linkedin.com/company/cereno-scientific-ab/",
      "size_in_visualization": "medium",
      "image_path": "images/cereno.png",
      "mission_statement": "Cereno Scientific is a clinical stage biotech company within cardiovascular diseases. The lead drug candidate, CS1, is a Phase II candidate in development for the treatment of the rare disease pulmonary arterial hypertension (PAH). CS1 is an HDAC (histone deacetylase) inhibitor that acts as an epigenetic modulator with pressure-reducing, reverse-remodeling, anti-inflammatory, anti-fibrotic and anti-thrombotic properties, all relevant for PAH. Cereno also has two promising preclinical drug candidates in development for cardiovascular disease through research collaborations with the University of Michigan. Targeted at treating cardiovascular disease, drug candidate CS585 is a stable, selective, and potent prostacyclin receptor agonist and drug candidate CS014 is an HDAC inhibitor with epigenetic effects. The company is listed on the Swedish Spotlight Stock Market (CRNO B)."
    },
    {
      "group": "Drugs",
      "ecosystem": "BioVentureHub",
      "company_name": "Corline Biomedical",
      "id": "Corline_Biomedical",
      "turnover_sek": 17300000,
      "amount_of_employees": 9,
      "type_of_company": "Drugs, Med Tech",
      "operationa_focus": "R&D",
      "value_chain": "Research",
      "therapy_areas": "Transplantation, Regenerative Medicine",
      "area": "Diabetes",
      "financing": "Listed",
      "ceo": "Nittmar, Henrik",
      "company_logo": "https://www.azbioventurehub.com/content/dam/bioventurehub/images/logo/corline-biomedical.jpg/jcr:content/renditions/cq5dam.web.320.corline-biomedical.jpg",
      "image_path": "images_cropped/corlinebiomedical_cropped.png",
      "company_website": "https://www.corline.se/home",
      "size_in_visualization": "medium",
      "mission_statement": "Corline Biomedical AB is a Nasdaq/OMX First North (CLBIO) listed company that develops, manufactures and markets heparin-based solutions to improve kidney transplantation, cell therapies and applications in the evolving field of regenerative medicine."
    },
    {
      "group": "Drugs",
      "ecosystem": "BioVentureHub",
      "company_name": "Emeriti Bio",
      "id": "Emeriti_Bio",
      "turnover_sek": 3300000,
      "amount_of_employees": 2,
      "type_of_company": "Drugs",
      "operationa_focus": "R&D",
      "value_chain": "Discovery",
      "therapy_areas": "Respiratory (with Vicore) & Cardiovascular Disease (with Cereno Scientific)",
      "area": "Gastrointestinal",
      "financing": "Private",
      "ceo": "Fryklund, Jan",
      "company_logo": "https://www.azbioventurehub.com/content/dam/bioventurehub/images/logo/Emeriti-Bio.jpg/jcr:content/renditions/cq5dam.web.320.Emeriti-Bio.jpg",
      "company_website": "https://www.emeritibio.se/",
      "company_linkedin": "LinkedIn Missing",
      "size_in_visualization": "medium",
      "image_path": "images/emeriti_bio.png",
      "mission_statement": "Emeriti Bio AB is a privately held sister company to Emeriti Pharma AB. The focus is on novel treatment options for heavy menstrual bleeding. Emeriti Bio AB is also developing molecules for validated pharmaceutical drug targets in different areas. Finally, Emeriti Bio AB provides consultancy services in chemistry, drug discovery and drug development."
    },
    {
      "group": "Drugs",
      "ecosystem": "BioVentureHub",
      "company_name": "Mendus",
      "id": "Mendus",
      "turnover_sek": 0,
      "amount_of_employees": 30,
      "type_of_company": "Drugs",
      "operationa_focus": "R&D",
      "value_chain": "Discovery",
      "therapy_areas": "Oncology",
      "area": "Oncology",
      "financing": "Listed",
      "ceo": "Manting, Erik Hans",
      "company_logo": "https://media.licdn.com/dms/image/D4E0BAQGbPjNHFEnGMw/company-logo_200_200/0/1683616749326?e=1696464000&v=beta&t=tXy_dke3NnsfGdZ51oq0mFA5DF2N8isy1zLQhIacImw",
      "company_website": "https://mendus.com/",
      "company_linkedin": "https://www.linkedin.com//company//mendus//",
      "size_in_visualization": "medium",
      "image_path": "images_cropped/mendus_cropped.png",
      "mission_statement": "Mendus is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies. The company's lead product ilixadencel, consisting of pro-inflammatory allogeneic dendritic cells, has the potential to become a backbone component of modern cancer combination treatments in a variety of solid tumor indications."
    },
    {
      "group": "Device",
      "ecosystem": "BioVentureHub",
      "company_name": "Mölnlycke Health Care",
      "id": "Mölnlycke_Health_Care",
      "turnover_sek": 14400000000,
      "amount_of_employees": 462,
      "type_of_company": "Med Tech",
      "operationa_focus": "Commercial",
      "value_chain": "Market",
      "therapy_areas": "Dermatology & Wound",
      "area": "Wound care",
      "financing": "Private (99% owned by Patricia Industries – part of Investor AB)",
      "ceo": "Rihter, Zlatko",
      "company_logo": "https://www.azbioventurehub.com/content/dam/bioventurehub/images/logo/Molnlycke.jpg/jcr:content/renditions/cq5dam.web.320.Molnlycke.jpg",
      "image_path": "images_cropped/molnlycke_cropped.png",
      "company_website": "https://www.molnlycke.com/",
      "company_linkedin": "https://www.linkedin.com/company/molnlyckehealthcare/",
      "size_in_visualization": "medium",
      "mission_statement": "Mölnlycke is a world leading medical solutions company. We develop and bring to market innovative wound care and surgical solutions along the entire continuum of care – from prevention to post-acute settings."
    },
    {
      "group": "Diagnostics",
      "ecosystem": "BioVentureHub",
      "company_name": "Q&Q Labs",
      "id": "Q&Q_Labs",
      "turnover_sek": 18200000,
      "amount_of_employees": 16,
      "type_of_company": "Expert Providers",
      "operationa_focus": "R&D",
      "value_chain": "Market",
      "therapy_areas": "N/A",
      "area": "Analytics",
      "financing": "Private",
      "ceo": "Wahlström, Rickard",
      "company_logo": "https://www.azbioventurehub.com/content/dam/bioventurehub/images/logo/qqlabs-ab.jpg/jcr:content/renditions/cq5dam.web.320.qqlabs-ab.jpg",
      "company_website": "https://qandqlabs.se//",
      "company_linkedin": "https://www.linkedin.com/company/q&q-labs-ab/",
      "size_in_visualization": "medium",
      "image_path": "images_cropped/qqlabs_cropped.png",
      "mission_statement": "Q&Q Labs offer bespoke analyses within organic chemistry. We develop customer specific analysis methods for characterization and quantification of organic substances for producers and importers of primarily pharmaceuticals and medical device. While specializing in method development on chromatography/mass spectrometry instruments we also have equipment for batch control/release testing of pharmaceuticals or pharm dev. We are audited for applicable parts of GMP, GLP & GCP "
    },
    {
      "group": "Device",
      "ecosystem": "BioVentureHub",
      "company_name": "Waters Sverige",
      "id": "Waters_Sverige",
      "turnover_sek": 343000000,
      "amount_of_employees": 61,
      "type_of_company": "Expert Providers",
      "operationa_focus": "R&D",
      "value_chain": "Market",
      "therapy_areas": "N/A",
      "area": "Analytics",
      "financing": "Listed",
      "ceo": "Turner, Christina Charlotte Lindved",
      "company_logo": "https://media.licdn.com/dms/image/D4E0BAQEARO58xA-kOQ/company-logo_200_200/0/1688172998415?e=1696464000&v=beta&t=oEggaf4YXU77I9lJMU6wVuyN9WdCgStn-CCw1SWLxs4",
      "image_path": "images/waters.png",
      "company_website": "https://www.waters.com/nextgen/se/en.html",
      "company_linkedin": "https://www.linkedin.com/company/waters/",
      "size_in_visualization": "medium",
      "mission_statement": "Waters Corporation, a leading specialty measurement company, has pioneered chromatography, mass spectrometry, and thermal analysis innovations serving the life, materials, and food sciences for more than 60 years. With more than 7,000 employees worldwide, Waters operates directly in 35 countries, including 15 manufacturing facilities, and with products available in more than 100 countries."
    },
    {
      "group": "Digital",
      "ecosystem": "BioVentureHub",
      "company_name": "Albus Health",
      "id": "Albus_Health",
      "turnover_sek": 2500000,
      "amount_of_employees": 4,
      "keywords": "contactless nocturnal device, respiratory rate, coughair quality, Biomarkers",
      "type_of_company": "Med Tech, Digital",
      "operationa_focus": "R&D",
      "value_chain": "Market",
      "therapy_areas": "Respiratory",
      "area": "Respiratory",
      "financing": "Private",
      "ceo": "Udani, Mikesh",
      "company_logo": "https://media.licdn.com/dms/image/C4E0BAQG8fm5Gwqngyw/company-logo_200_200/0/1567093418232?e=1696464000&v=beta&t=2KS-lBTJt5ULqmmDGjxOPpeyG45Opq1KwRA8nDsi9xM",
      "image_path": "images_cropped/albus_health_cropped.png",
      "company_website": "https://albushealth.com/",
      "company_linkedin": "https://www.linkedin.com/company/albushealth/",
      "size_in_visualization": "medium",
      "mission_statement": "Albus Health makes contactless nocturnal monitoring systems (Albus Home) that automatically monitor a range of physiological and environmental metrics without the patients having to do or wear anything. Using a small bedside device and a range of algorithms, the system monitors metrics such as respiration, coughing and wheezing, as well as information such as air quality, temperature and humidity. Whether it's a 5 year-old child or a 95 year-old elderly, Albus Home can be used with anyone, anywhere and as long as needed. This helps collect continuous and objective evidence from participants' homes in clinical trials without needing clinical visits. In healthcare, it provides exciting opportunities for continuous monitoring of a range of chronic conditions to provide a diagnosis as well as early warning signs of worsening several days prior to an emergency, so patients can stay healthy at home."
    },
    {
      "group": "Diagnostics",
      "ecosystem": "BioVentureHub",
      "company_name": "Amferia",
      "id": "Amferia",
      "turnover_sek": 1400000,
      "amount_of_employees": 5,
      "keywords": "antibacterial material, patented technology, wound care product",
      "type_of_company": "Med Tech",
      "operationa_focus": "R&D",
      "value_chain": "Market",
      "therapy_areas": "Dermatology & Wound, Infection",
      "area": "Antimicrobial",
      "financing": "Private",
      "ceo": "Rajasekaran, Anand",
      "company_logo": "https://www.azbioventurehub.com/content/dam/bioventurehub/images/logo/Amferia%20Header.png/jcr:content/renditions/cq5dam.web.320.Amferia%20Header.png",
      "company_website": "https://www.amferia.com/",
      "company_linkedin": "https://www.linkedin.com/company//amferia/",
      "size_in_visualization": "medium",
      "image_path": "images_cropped/amferia_cropped.png",
      "mission_statement": "Amferia’s proprietary patented technology is a new and effective antibacterial material. The material consists of bioinspired and amphiphilic antibacterial polymers that target and rapidly kill bacteria upon contact, including numerous antibiotic resistant bacteria like MRSA and MDR E. Coli."
    },
    {
      "group": "Drugs",
      "ecosystem": "BioVentureHub",
      "company_name": "Apconix",
      "id": "Apconix",
      "turnover_sek": 0,
      "amount_of_employees": 1,
      "keywords": "Consultation opportunity for Clinical Pharmacology & Safety Sciences",
      "type_of_company": "Expert Providers",
      "operationa_focus": "R&D",
      "value_chain": "Research",
      "therapy_areas": "N/A",
      "area": "Safety",
      "financing": "Private",
      "ceo": "Knight, Richard",
      "company_logo": "https://www.azbioventurehub.com/content/dam/bioventurehub/images/logo/Apconix.jpg/jcr:content/renditions/cq5dam.web.320.Apconix.jpg",
      "image_path": "images_cropped/apconix_cropped.png",
      "company_website": "https://www.apconix.com/",
      "company_linkedin": "https://www.linkedin.com/company/apconix/",
      "size_in_visualization": "medium",
      "mission_statement": "ApconiX was formed in 2015 by three AstraZeneca colleagues with the drive and ambition to create a world-renowned company known for its expertise in nonclinical safety toxicology and ion channel electrophysiology.  The company is founded on the skills and experience of a growing team with a wide range of expertise in preclinical drug safety."
    },
    {
      "group": "Drugs",
      "ecosystem": "BioVentureHub",
      "company_name": "Betagenon",
      "id": "Betagenon",
      "turnover_sek": 7900000,
      "amount_of_employees": 3,
      "type_of_company": "Drugs",
      "operationa_focus": "R&D",
      "value_chain": "Discovery",
      "therapy_areas": "CVRM",
      "area": "Aging",
      "financing": "Private",
      "ceo": "Hall, James",
      "company_logo": "https://www.azbioventurehub.com/content/dam/bioventurehub/images/logo/Betagenon_logoo.jpg/jcr:content/renditions/cq5dam.web.320.Betagenon_logoo.jpg",
      "company_website": "Missing",
      "company_linkedin": "LinkedIn Missing",
      "size_in_visualization": "medium",
      "image_path": "images/betagenon.png",
      "mission_statement": "Betagenon is a Swedish biopharmaceutical company focused on the development of AMP-activated protein kinase (AMPK) activator compounds to treat metabolic & cardiorenal and inflammatory disorders associated with obesity and aging."
    },
    {
      "group": "Diagnostics",
      "ecosystem": "BioVentureHub",
      "company_name": "Cline Scientific",
      "id": "Cline_Scientific",
      "turnover_sek": 2900000,
      "amount_of_employees": 2,
      "type_of_company": "Med Tech, Diagnostics",
      "operationa_focus": "R&D",
      "value_chain": "Research",
      "therapy_areas": "N/A/ Oncology",
      "area": "Oncology",
      "financing": "Listed",
      "ceo": "Sundh, Patrik",
      "company_logo": "https://www.azbioventurehub.com/content/dam/bioventurehub/images/logo/cline-ab.jpg/jcr:content/renditions/cq5dam.web.320.cline-ab.jpg",
      "company_website": "https://www.clinescientific.com//",
      "company_linkedin": "https://www.linkedin.com/company/cline-technologies/",
      "size_in_visualization": "medium",
      "image_path": "images_cropped/cline_cropped.png",
      "mission_statement": "Cline Scientific is an innovative life science company focusing on the use of nanotechnology and nanoscale surface gradients to improve stem cell and cancer research. The company is using nanoscale surface engineering to support cell biology research, through two main applications; stem cell differentiation and culture, and migration in cancer cell research."
    },
    {
      "group": "Digital",
      "ecosystem": "BioVentureHub",
      "company_name": "Datametrix",
      "id": "Datametrix",
      "turnover_sek": 280000000,
      "amount_of_employees": 1,
      "type_of_company": "Digital, Expert Providers",
      "operationa_focus": "Commercial",
      "value_chain": "Discovery",
      "therapy_areas": "N/A",
      "area": "Digital",
      "financing": "Private",
      "ceo": "El Rhali, Ahmed",
      "company_logo": "https://www.azbioventurehub.com/content/dam/bioventurehub/images/logo/data-metrix.jpg/jcr:content/renditions/cq5dam.web.320.data-metrix.jpg",
      "image_path": "images_cropped/datametrix_cropped.png",
      "company_website": "https://datametrix.ch/",
      "company_linkedin": "https://www.linkedin.com/company/datametrix-ag/",
      "size_in_visualization": "medium",
      "mission_statement": "Founded in 2003, datametrix is a Swiss clinical research organization with a strong heritage in statistical analysis and programming, clinical data management and medical writing. With more than 13 years of experience, we are well-established alternative to top tier CROs, delivering high quality and cost-effective services to pharmaceutical, life science and biotech industries."
    },
    {
      "group": "Drugs",
      "ecosystem": "BioVentureHub",
      "company_name": "Ectin Research",
      "id": "Ectin_Research",
      "turnover_sek": 2200000,
      "amount_of_employees": 1,
      "type_of_company": "Drugs",
      "operationa_focus": "R&D",
      "value_chain": "Discovery",
      "therapy_areas": "Oncology",
      "area": "Oncology",
      "financing": "Listed",
      "ceo": "Sjöblom-Hallén, Anna",
      "company_logo": "https://www.azbioventurehub.com/content/dam/bioventurehub/images/logo/Ectin%20Research%20logo%20dec%202020.png/jcr:content/renditions/cq5dam.web.320.Ectin%20Research%20logo%20dec%202020.png",
      "company_website": "https://www.ectinresearch.com//",
      "company_linkedin": "https://www.linkedin.com/company/ectin-research/",
      "size_in_visualization": "medium",
      "image_path": "images_cropped/ectin_cropped.png",
      "mission_statement": "Ectin Research is a cancer therapy company with a technology based on repositioning of approved drugs and an initial efficacy observation in a bladder cancer patient with spread and incurable disease. The initial aim of the company is to focus on treating metastasized bladder cancer to prove the efficacy of the therapy. Following this, Ectin Research plans to explore the treatment of other cancer indications."
    },
    {
      "group": "Drugs",
      "ecosystem": "BioVentureHub",
      "company_name": "Inorbittx",
      "id": "Inorbittx",
      "turnover_sek": 5200000,
      "amount_of_employees": 1,
      "type_of_company": "Drugs",
      "operationa_focus": "R&D",
      "value_chain": "Research",
      "therapy_areas": "CVRM, with focus on NASH",
      "area": "Cardiovascular",
      "financing": "Private",
      "ceo": "Benthem, Bert",
      "company_logo": "https://www.azbioventurehub.com/content/dam/bioventurehub/images/logo/inorbittx.jpg/jcr:content/renditions/cq5dam.web.320.inorbittx.jpg",
      "company_website": "https://inorbittx.com/",
      "company_linkedin": "LinkedIn Missing",
      "size_in_visualization": "medium",
      "image_path": "images/inorbittx.png",
      "mission_statement": "Inorbit Therapeutics AB discovers and develops small molecule therapeutics based on molecules with proven clinical efficacy in humans. Inorbit focuses currently on compounds for the treatment of Type 2 Diabetes Mellitus, Gout, Fatty Liver Disease (NAFLD / NASH), and inflammatory diseases."
    },
    {
      "group": "Device",
      "ecosystem": "BioVentureHub",
      "company_name": "In Singulo Solutions",
      "id": "In_Singulo_Solutions",
      "turnover_sek": 1100000,
      "amount_of_employees": 1,
      "type_of_company": "Med Tech",
      "operationa_focus": "R&D",
      "value_chain": "Research",
      "therapy_areas": "N/A",
      "area": "Analytics",
      "financing": "Private",
      "ceo": "Holm, Karl-Johan",
      "company_logo": "https://www.azbioventurehub.com/content/dam/bioventurehub/images/logo/Insingulo-new-logo.png/jcr:content/renditions/cq5dam.web.320.Insingulo-new-logo.png",
      "company_website": "https://insingulo.com//",
      "company_linkedin": "https://www.linkedin.com/company/insingulo-ab/",
      "size_in_visualization": "medium",
      "image_path": "images_cropped/insingulo_cropped.png",
      "mission_statement": "At InSingulo, we specialize in the characterization of drug interactions with complex targets down to the single molecule level. Our biosensing technology allows for drug profiling on membrane proteins embedded in their native environment. We enable drug screening programs against membrane proteins and other challenging therapeutic targets.InSingulo was founded in 2017 following a collaboration between Chalmers University of Technology and AstraZeneca, bringing a new class of biosensing technology to overcome some of the toughest challenges in drug discovery."
    },
    {
      "group": "Digital",
      "ecosystem": "BioVentureHub",
      "company_name": "Intelligent Implants",
      "id": "Intelligent_Implants",
      "turnover_sek": 7900000,
      "amount_of_employees": 7,
      "type_of_company": "Med Tech, Digital",
      "operationa_focus": "R&D",
      "value_chain": "Market",
      "therapy_areas": "Orthopaedic",
      "area": "Digital",
      "financing": "Private",
      "ceo": "Zellmer, John",
      "company_logo": "https://www.azbioventurehub.com/content/dam/bioventurehub/images/logo/Intelligents_implants_logo_COLOR.png/jcr:content/renditions/cq5dam.web.320.Intelligents_implants_logo_COLOR.png",
      "company_website": "https://intelligentimplants.ie//",
      "company_linkedin": "https://www.linkedin.com/company/intelligent-implants/",
      "size_in_visualization": "medium",
      "image_path": "images_cropped/intelligent_implants_cropped.png",
      "mission_statement": "Intelligent Implants is developing a wireless implantable bioelectronic stimulation platform incorporated into standard orthopedic implants. With excellent pre-clinical trial outcomes, Intelligent Implants is now looking to bring its breakthrough technology into the clinic."
    },
    {
      "group": "Drugs",
      "ecosystem": "BioVentureHub",
      "company_name": "I-Tech",
      "id": "I-Tech",
      "turnover_sek": 53500000,
      "amount_of_employees": 9,
      "type_of_company": "Med Tech",
      "operationa_focus": "Commercial",
      "value_chain": "Market",
      "therapy_areas": "N/A",
      "area": "Antifouling",
      "financing": "Listed",
      "ceo": "Chaabane, Philip",
      "company_logo": "https://www.azbioventurehub.com/content/dam/bioventurehub/images/logo/i-tech.jpg/jcr:content/renditions/cq5dam.web.320.i-tech.jpg",
      "image_path": "images_cropped/itech_cropped.png",
      "company_website": "https://i-tech.se/",
      "company_linkedin": "https://www.linkedin.com/company/i-tech-ab/",
      "size_in_visualization": "medium",
      "mission_statement": "I-Tech, develops, manufacture and market an antifouling substance, Selektope. Selektope has proven remarkable fouling protection even in the most demanding situations and in very low concentrations in marine paints. Our vision is to be a global developer and supplier of marine biocides with an extended market share."
    },
    {
      "group": "Device",
      "ecosystem": "BioVentureHub",
      "company_name": "Kromnigon",
      "id": "Kromnigon",
      "turnover_sek": 500000,
      "amount_of_employees": 2,
      "type_of_company": "Med Tech",
      "operationa_focus": "Commercial",
      "value_chain": "Research",
      "therapy_areas": "N/A",
      "area": "Analytics",
      "financing": "Private",
      "ceo": "Fogelstrand, Per",
      "company_logo": "https://www.azbioventurehub.com/content/dam/bioventurehub/images/logo/Kromningon%20ny.png/jcr:content/renditions/cq5dam.web.320.Kromningon%20ny.png",
      "company_website": "https://kromnigon.com//",
      "company_linkedin": "https://www.linkedin.com//company//kromnigon-ab//",
      "size_in_visualization": "medium",
      "image_path": "images_cropped/kromnigon_cropped.png",
      "mission_statement": "Kromnigon AB develops a new generation of reagents for multicolor microscopy based on its patented technology StreptaClick. The field of multicolor microscopy has skyrocketed due to personalized medicine and its need for understanding cell interactions in tissues. Kromnigon was founded in 2015 and has since been supported by for example GU Ventures, Vinnova, and Almi. We have several new products on the way and will during 2022 raise new capital to expand marketing."
    },
    {
      "group": "Device",
      "ecosystem": "BioVentureHub",
      "company_name": "KTH Nanobiotech",
      "id": "KTH_Nanobiotech",
      "turnover_sek": 14400000,
      "amount_of_employees": 12,
      "type_of_company": "Academia, Med Tech",
      "operationa_focus": "Academia",
      "value_chain": "Research",
      "therapy_areas": "N/A",
      "area": "Nanotechnology",
      "financing": "Private",
      "ceo": "Jönsson, Håkan",
      "company_logo": "https://media.licdn.com/dms/image/C4D0BAQGkcfLVY-zvDA/company-logo_200_200/0/1534319667361?e=1696464000&v=beta&t=BIxif65vuxX7v1_YKsj3hkmT2oOfTEatbNy8Nt5qN1E",
      "image_path": "images_cropped/kth.png",
      "company_website": "https://www.kth.se/pro/nanobio/division-of-nanobiotechnology-1.185383",
      "company_linkedin": "https://www.linkedin.com/school/kth/",
      "size_in_visualization": "medium",
      "mission_statement": "The aim of the lab established by the KTH Royal Institute of Technology in Stockholm is to test and scale-up an innovative, nanoscale, microfluidic technology platform for large-scale drug compound screening in a pharmaceutical company setting."
    },
    {
      "group": "Device",
      "ecosystem": "BioVentureHub",
      "company_name": "Lucero",
      "id": "Lucero",
      "turnover_sek": 900000,
      "amount_of_employees": 2,
      "type_of_company": "Med Tech",
      "operationa_focus": "R&D",
      "value_chain": "Research",
      "therapy_areas": "N/A",
      "area": "Analytics",
      "financing": "Private",
      "ceo": "Jacklin, Christopher",
      "company_logo": "https://www.azbioventurehub.com/content/dam/bioventurehub/images/logo/Lucero%20ny.png/jcr:content/renditions/cq5dam.web.480.Lucero%20ny.png",
      "image_path": "images_cropped/lucero_cropped.png",
      "company_website": "https://www.lucerobio.com/",
      "company_linkedin": "https://www.linkedin.com/company/lucero/",
      "size_in_visualization": "medium",
      "mission_statement": "Lucero is developing a cell handling platform to enable the use of miniature organ models in preclinical, high-throughput screening. The aim is to enable pharmaceutical companies to gather near-patient data earlier in the drug development timeline to increase the likelihood of success during clinical trials."
    },
    {
      "group": "Drugs",
      "ecosystem": "BioVentureHub",
      "company_name": "Metabogen",
      "id": "Metabogen",
      "turnover_sek": 1000000,
      "amount_of_employees": 6,
      "type_of_company": "Drugs",
      "operationa_focus": "Commercial",
      "value_chain": "Market",
      "therapy_areas": "Pre-diabetes, Immuno-oncology",
      "area": "Metabolism",
      "financing": "Financed by BioGaia that is listed",
      "ceo": "Malcus, Sara",
      "company_logo": "https://www.azbioventurehub.com/content/dam/bioventurehub/images/logo/Metabogen.jpg/jcr:content/renditions/cq5dam.web.320.Metabogen.jpg",
      "company_website": "https://www.metabogen.se/",
      "company_linkedin": "https://www.linkedin.com/company/metabogen-ab/",
      "size_in_visualization": "medium",
      "image_path": "images_cropped/metabogen_cropped.png",
      "mission_statement": "Addressing the microbiome, MetaboGen is creating breakthrough opportunities to develop next generation probiotics. The company was founded based on world leading science from the labs of Professor Fredrik Bäckhed (University of Gothenburg) and Professor Jens B Nielsen (Chalmers University of Technology), to provide commercial access to metagenome research and development. Today, MetaboGen is a wholly owned subsidiary of the Swedish probiotic company BioGaia AB."
    },
    {
      "group": "Device",
      "ecosystem": "BioVentureHub",
      "company_name": "Nanolyze",
      "id": "Nanolyze",
      "turnover_sek": 1400000,
      "amount_of_employees": 2,
      "type_of_company": "Med Tech",
      "operationa_focus": "R&D",
      "value_chain": "Discovery",
      "therapy_areas": "N/A",
      "area": "Analytics",
      "financing": "Private",
      "ceo": "Löfgren, Nils",
      "company_logo": "https://www.azbioventurehub.com/content/dam/bioventurehub/images/logo/Nanolyze_logo-900x400.png/jcr:content/renditions/cq5dam.web.320.Nanolyze_logo-900x400.png",
      "image_path": "images_cropped/nanolyze_cropped.png",
      "company_website": "https://www.nanolyze.se/",
      "company_linkedin": "https://www.linkedin.com//company/nanolyze/",
      "size_in_visualization": "medium",
      "mission_statement": "Nanolyze provides new ultra-sensitive technology for analyzing nanoparticle uptake and release of substances. A necessary step for making future medicine more precise and efficient. Nanoparticle analysis often requires several processing steps and a single measurement can be time consuming. Therefore, we have our starting point in waveguide technology, and focus on simple setup, minimal preparation need, and intuitive analysis methods. Currently, we focus on applications for biological nanoparticles and we act in the overlapping field of physics and biology."
    },
    {
      "group": "Diagnostics",
      "ecosystem": "BioVentureHub",
      "company_name": "CII / Chemical Imaging Infrastructure",
      "id": "CII_//_Chemical_Imaging_Infrastructure",
      "turnover_sek": 2900000,
      "amount_of_employees": 2,
      "type_of_company": "Academia, Med Tech",
      "operationa_focus": "Academia",
      "value_chain": "Research",
      "therapy_areas": "N/A",
      "area": "Imaging",
      "financing": "Private",
      "ceo": "Malmberg, Per",
      "company_logo": "https://www.azbioventurehub.com/content/dam/bioventurehub/images/logo/NanoSIMS_logo_small.png/jcr:content/renditions/cq5dam.web.320.NanoSIMS_logo_small.png",
      "company_website": "https://www.chalmers.se/en/infrastructure/cii/about-us/",
      "company_linkedin": "https://www.linkedin.com/company/chemical-imaging-infrastructure/",
      "size_in_visualization": "medium",
      "image_path": "images_cropped/cii_cropped.png",
      "mission_statement": "Chalmers University of Technology/Gothenburg University have located their NanoSIMS laboratory in the BioVentureHub. The lab offers unique, ultra-high spatial chemical imaging giving true sub-cellular localisation of molecules in cells and tissue, as well as quantitative isotopic imaging for many other applications ranging from geology to materials science."
    },
    {
      "group": "Drugs",
      "ecosystem": "BioVentureHub",
      "company_name": "Oligonova",
      "id": "OligoNova",
      "turnover_sek": 0,
      "amount_of_employees": 7,
      "type_of_company": "Academia, Med Tech",
      "operationa_focus": "Academia",
      "value_chain": "Research",
      "therapy_areas": "N/A",
      "area": "Pharmaceuticals",
      "financing": "Private",
      "ceo": "Matsson, Pär",
      "company_logo": "https://www.azbioventurehub.com/content/dam/bioventurehub/images/meetthecompanies/Oligonova_logo.png/jcr:content/renditions/cq5dam.web.320.Oligonova_logo.png",
      "company_website": "https://oligonova.org/",
      "company_linkedin": "https://www.linkedin.com/company/oligonova-hub/",
      "size_in_visualization": "medium",
      "image_path": "images_cropped/oligonova_cropped.png",
      "mission_statement": "OligoNova is a Swedish initiative addressing challenges in Research & Development of therapeutic oligonucleotides and supporting the development of novel therapies. OligoNova has the vision to deliver R&D innovations that will result in new patents, start-up companies and innovate treatments to patients."
    },
    {
      "group": "Device",
      "ecosystem": "BioVentureHub",
      "company_name": "Ondosis",
      "id": "Ondosis",
      "turnover_sek": 19300000,
      "amount_of_employees": 9,
      "type_of_company": "Med Tech, Digital",
      "operationa_focus": "R&D",
      "value_chain": "Market",
      "therapy_areas": "N/A",
      "area": "Dosing",
      "financing": "Private",
      "ceo": "Olovsson, Martin",
      "company_logo": "https://www.azbioventurehub.com/content/dam/bioventurehub/images/logo/Ondosis_new_logo_horiz.jpg/jcr:content/renditions/cq5dam.web.320.Ondosis_new_logo_horiz.jpg",
      "image_path": "images_cropped/ondosis_cropped.png",
      "company_website": "https://www.ondosis.com/",
      "company_linkedin": "https://www.linkedin.com/company/ondosis/",
      "size_in_visualization": "medium",
      "mission_statement": "Building on a spin out from AstraZeneca, OnDosis is developing a smart drug delivery platform for personalized and connected dosing of medicines. The OnDosis devices combine tailored and flexible dosing and mobile health technologies with the objective to improve treatment outcomes for a wide array of diseases and patients. The first OnDosis product is under development with the aim to reach the market in 2020"
    },
    {
      "group": "Diagnostics",
      "ecosystem": "BioVentureHub",
      "company_name": "Profundus",
      "id": "Profundus",
      "turnover_sek": 7800000,
      "amount_of_employees": 7,
      "type_of_company": "Med Tech, Diagnostics",
      "operationa_focus": "R&D",
      "value_chain": "Research",
      "therapy_areas": "Ophthalmology",
      "area": "Analytics",
      "financing": "Private",
      "ceo": "Lindström, Åsa",
      "company_logo": "https://www.azbioventurehub.com/content/dam/bioventurehub/images/logo/Profundus_logo-900x400.jpg/jcr:content/renditions/cq5dam.web.320.Profundus_logo-900x400.jpg",
      "company_website": "https://www.profundusimaging.com/",
      "company_linkedin": "https://www.linkedin.com/company/profundus-ab-sweden/",
      "size_in_visualization": "medium",
      "image_path": "images_cropped/profundus_cropped.png",
      "mission_statement": "Profundus was founded by academics combining eye research and technology in the area of astronomy to address the development of high resolution, adaptive optics for retinal imaging. The company is developing an innovative system to image single cells and the smallest capillaries in the retina. The objective is to provide clinical and academic researchers with a clearer view of diseases that can cause vision impairment and/or blindness"
    },
    {
      "group": "Device",
      "ecosystem": "BioVentureHub",
      "company_name": "Promimic",
      "id": "Promimic",
      "turnover_sek": 8400000,
      "amount_of_employees": 13,
      "type_of_company": "Med Tech",
      "operationa_focus": "R&D",
      "value_chain": "Discovery",
      "therapy_areas": "Dental & Orthopaedic",
      "area": "Implants",
      "financing": "Listed",
      "ceo": "Larsson, Magnus",
      "company_logo": "https://media.licdn.com/dms/image/C4D0BAQGNeMDAsSOduw/company-logo_200_200/0/1519917156696?e=2147483647&v=beta&t=-0qaVjnyjDc41bIDrnjUuxdSff7-MfhUYzQKTvESlj4",
      "image_path": "images_cropped/promimic_cropped.png",
      "company_website": "https://promimic.com/",
      "company_linkedin": "https://www.linkedin.com/company/promimic/",
      "size_in_visualization": "medium",
      "mission_statement": "Promimic has developed a process that makes it possible to modify all types of implant materials and geometries with a nanometer-thin surface of synthetic bone minerals; HAnano Surface. It is based on the substance hydroxyapatite (HA), which by size, shape, structure and chemistry mimics the living bone tissue; The HAnano Surface is licensed to dental and orthopaedic implants companies. Promimic is a spin-off company based on research from Chalmers University of Technology."
    },
    {
      "group": "Digital",
      "ecosystem": "BioVentureHub",
      "company_name": "Synergon",
      "id": "Synergon",
      "turnover_sek": 30400000,
      "amount_of_employees": 7,
      "type_of_company": "Expert Providers",
      "operationa_focus": "Commercial",
      "value_chain": "Market",
      "therapy_areas": "N/A",
      "area": "Intellectual Property",
      "financing": "Private",
      "ceo": "Faijerson Säljö, Jonas",
      "company_logo": "https://www.azbioventurehub.com/content/dam/bioventurehub/images/logo/Synegon_logo.png/jcr:content/renditions/cq5dam.web.320.Synegon_logo.png",
      "image_path": "images_cropped/synergon_cropped.png",
      "company_website": "https://www.synergon.se/se",
      "company_linkedin": "https://www.linkedin.com/company/synergon_2/",
      "size_in_visualization": "medium",
      "mission_statement": "Synergon offers qualified strategic Intellectual Property (IP) advice and IP portfolio management, with a focus on patents, trademarks and trade secrets. Our strength lies in the Life Science area, specifically in pharmaceuticals, biotechnology and Medtech, as well as in digital innovations.  We see the big picture around IP, always maintaining a business-oriented perspective in order to ensure a cost efficient and commercially relevant IP protection for our clients"
    },
    {
      "group": "Drugs",
      "ecosystem": "Alumni",
      "company_name": "CFM Pharma",
      "id": "cfm_pharma",
      "turnover_sek": 1730000,
      "amount_of_employees": 300,
      "keywords": "",
      "type_of_company": "Drugs",
      "operational_focus": "",
      "value_chain": "",
      "therapy_areas": "CVRM (myocardial Infarction as primary indication) ",
      "area": "",
      "financing": "Private",
      "ceo": "Lekhram Changoer",
      "company_logo": "images/cfm_pharma.png",
      "company_website": "https://cfmpharma.com/",
      "company_linkedIn": "",
      "size_in_visualization": "medium",
      "image_path": "images/cfm_pharma.png"
    },
    {
      "group": "Drugs",
      "ecosystem": "Alumni",
      "company_name": "Mindforce Game Lab",
      "id": "mindforce_game_lab",
      "turnover_sek": 1730000,
      "amount_of_employees": 300,
      "keywords": "",
      "type_of_company": "Digital Health",
      "operational_focus": "",
      "value_chain": "",
      "therapy_areas": "N/A",
      "area": "",
      "financing": "Private",
      "ceo": "Anders Rabbe",
      "company_logo": "images/mindforce.jpg",
      "company_website": "https://mindforcegamelab.com/",
      "company_linkedIn": "",
      "size_in_visualization": "medium",
      "image_path": "images/mindforce.jpg"
    },
    {
      "group": "Drugs",
      "ecosystem": "Alumni",
      "company_name": "Neurametrix",
      "id": "neurametrix",
      "turnover_sek": 1730000,
      "amount_of_employees": 300,
      "keywords": "",
      "type_of_company": "Med Tech",
      "operational_focus": "",
      "value_chain": "",
      "therapy_areas": "Neurology",
      "area": "",
      "financing": "Listed",
      "ceo": "Daniel Poté",
      "company_logo": "images/neurametrix.jpg",
      "company_website": "https://www.neurametrix.com/",
      "company_linkedIn": "",
      "size_in_visualization": "medium",
      "image_path": "images/neurametrix.jpg"
    },
    {
      "group": "Drugs",
      "ecosystem": "GoCo",
      "company_name": "GoCo Company",
      "id": "goco_company_one",
      "turnover_sek": 1730000,
      "amount_of_employees": 300,
      "keywords": "",
      "type_of_company": "Med Tech",
      "operational_focus": "",
      "value_chain": "",
      "therapy_areas": "Neurology",
      "area": "",
      "financing": "Listed",
      "ceo": "",
      "company_logo": "images/goco.png",
      "company_website": "",
      "company_linkedIn": "",
      "size_in_visualization": "medium",
      "image_path": "images/goco.png"
    }
  ],
  "links": []
}
